ES2399931T3 - Diagnóstico y estratificación de riesgo del síndrome coronario agudo mediante CT-proET-1 en combinación con NTproBNP - Google Patents
Diagnóstico y estratificación de riesgo del síndrome coronario agudo mediante CT-proET-1 en combinación con NTproBNP Download PDFInfo
- Publication number
- ES2399931T3 ES2399931T3 ES07856155T ES07856155T ES2399931T3 ES 2399931 T3 ES2399931 T3 ES 2399931T3 ES 07856155 T ES07856155 T ES 07856155T ES 07856155 T ES07856155 T ES 07856155T ES 2399931 T3 ES2399931 T3 ES 2399931T3
- Authority
- ES
- Spain
- Prior art keywords
- myocardial infarction
- diagnosis
- acute coronary
- coronary syndrome
- post
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000004476 Acute Coronary Syndrome Diseases 0.000 title claims abstract description 47
- 238000003745 diagnosis Methods 0.000 title claims abstract description 35
- 238000013517 stratification Methods 0.000 title claims abstract description 30
- 108010008126 C-terminal proendothelin-1 Proteins 0.000 title claims abstract 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 title claims description 27
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 36
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims abstract description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 29
- 102400001263 NT-proBNP Human genes 0.000 claims description 21
- 239000003550 marker Substances 0.000 claims description 21
- 238000004393 prognosis Methods 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 11
- 102100034296 Natriuretic peptides A Human genes 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000000747 cardiac effect Effects 0.000 claims description 7
- 101710187802 Natriuretic peptides B Proteins 0.000 claims description 6
- 102100036836 Natriuretic peptides B Human genes 0.000 claims description 6
- 238000003748 differential diagnosis Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940124645 emergency medicine Drugs 0.000 claims description 5
- 210000004165 myocardium Anatomy 0.000 claims description 5
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 4
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000001452 natriuretic effect Effects 0.000 claims description 4
- 230000002644 neurohormonal effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108010062374 Myoglobin Proteins 0.000 claims description 3
- -1 NT-proANP Proteins 0.000 claims description 3
- 101710187800 Natriuretic peptides A Proteins 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 102000004420 Creatine Kinase Human genes 0.000 claims description 2
- 108010042126 Creatine kinase Proteins 0.000 claims description 2
- 102400000921 Gastrin Human genes 0.000 claims description 2
- 108010052343 Gastrins Proteins 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 claims description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 claims description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 2
- 108010048233 Procalcitonin Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 2
- 108010072272 proendothelin 1 Proteins 0.000 claims description 2
- 108010001670 prosomatostatin Proteins 0.000 claims description 2
- GGYTXJNZMFRSLX-UHFFFAOYSA-N prosomatostatin Chemical compound C1CCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)NCC(=O)NC2C(NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(C(=O)NC(CO)C(=O)NC(CSSC2)C(O)=O)C(C)O)C(C)O)=O)N1C(=O)C(C)NC(=O)C(CCSC)NC(=O)C(C)NC(=O)C1CCCN1C(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(N)CO GGYTXJNZMFRSLX-UHFFFAOYSA-N 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000003896 Myeloperoxidases Human genes 0.000 claims 1
- 102100030856 Myoglobin Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 21
- 206010019280 Heart failures Diseases 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 231100000517 death Toxicity 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 7
- 101800004490 Endothelin-1 Proteins 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102400000569 Myeloperoxidase Human genes 0.000 description 1
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 1
- 102100028427 Pro-neuropeptide Y Human genes 0.000 description 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012125 lateral flow test Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 108010088603 proneuropeptide Y Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000011818 severe chest pain Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006060835A DE102006060835A1 (de) | 2006-12-22 | 2006-12-22 | Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP |
| DE102006060835 | 2006-12-22 | ||
| PCT/DE2007/002313 WO2008077396A1 (de) | 2006-12-22 | 2007-12-22 | Diagnose und risikostratifizierung des akuten koronarsyndroms mittels ct-proet-1 in kombination mit nt-probnp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2399931T3 true ES2399931T3 (es) | 2013-04-04 |
Family
ID=39410311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07856155T Active ES2399931T3 (es) | 2006-12-22 | 2007-12-22 | Diagnóstico y estratificación de riesgo del síndrome coronario agudo mediante CT-proET-1 en combinación con NTproBNP |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8524463B2 (enExample) |
| EP (1) | EP2122365B1 (enExample) |
| JP (1) | JP5190067B2 (enExample) |
| CN (1) | CN101646945B (enExample) |
| DE (1) | DE102006060835A1 (enExample) |
| ES (1) | ES2399931T3 (enExample) |
| WO (1) | WO2008077396A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| EP2016394A4 (en) | 2006-04-04 | 2013-04-24 | Singulex Inc | METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES |
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
| CN102428368B (zh) * | 2009-05-05 | 2015-04-22 | B.R.A.H.M.S有限公司 | 患有内皮功能/功能障碍相关疾病的患者的基于血管活性激素的分层 |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| US20120321595A1 (en) | 2009-11-09 | 2012-12-20 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| WO2013013758A1 (en) | 2011-07-28 | 2013-01-31 | B.R.A.H.M.S. Gmbh | Mid-regional pro-atrial natriuretic peptide (pro-anp) for the identification patients with atrial fibrillation with an onset of less than 48 hours ago |
| US20140206632A1 (en) * | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1327228C (zh) * | 1999-01-29 | 2007-07-18 | 罗赫诊断器材股份有限公司 | 鉴定样品中的n－末端前bnp的方法 |
| AUPR005600A0 (en) * | 2000-09-12 | 2000-10-05 | University Of Sydney, The | Diagnostic assay |
| MXPA03004105A (es) | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| AU2003302132B2 (en) * | 2002-11-21 | 2008-02-21 | Inverness Medical Switzerland Gmbh | Bodily fluid markers of tissue hypoxia |
| GB0227179D0 (en) * | 2002-11-21 | 2002-12-24 | Univ Leicester | Bodily fluid markers of tissue hypoxia |
| DE10351238A1 (de) * | 2003-11-03 | 2005-06-02 | Roche Diagnostics Gmbh | Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern |
| ATE312351T1 (de) | 2004-02-13 | 2005-12-15 | Brahms Ag | Verfahren zur bestimmung der bildung von endothelinen zu zwecken der medizinischen diagnostik, sowie antikörper und kits für die durchführung eines solchen verfahrens |
| ES2300681T3 (es) * | 2004-07-22 | 2008-06-16 | Brahms Aktiengesellschaft | Procedimiento para el diagnostico y tratamiento de pacientes criticos con endotelina, agonistas de endotelina y antagonistas de adrenomedulina. |
-
2006
- 2006-12-22 DE DE102006060835A patent/DE102006060835A1/de not_active Withdrawn
-
2007
- 2007-12-22 JP JP2009541763A patent/JP5190067B2/ja not_active Expired - Fee Related
- 2007-12-22 WO PCT/DE2007/002313 patent/WO2008077396A1/de not_active Ceased
- 2007-12-22 EP EP07856155A patent/EP2122365B1/de active Active
- 2007-12-22 ES ES07856155T patent/ES2399931T3/es active Active
- 2007-12-22 US US12/520,166 patent/US8524463B2/en not_active Expired - Fee Related
- 2007-12-22 CN CN200780050549.XA patent/CN101646945B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100151504A1 (en) | 2010-06-17 |
| CN101646945A (zh) | 2010-02-10 |
| EP2122365B1 (de) | 2012-12-19 |
| US8524463B2 (en) | 2013-09-03 |
| DE102006060835A1 (de) | 2008-06-26 |
| EP2122365A1 (de) | 2009-11-25 |
| CN101646945B (zh) | 2014-06-04 |
| WO2008077396A1 (de) | 2008-07-03 |
| JP2010513880A (ja) | 2010-04-30 |
| HK1140547A1 (en) | 2010-10-15 |
| JP5190067B2 (ja) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2399931T3 (es) | Diagnóstico y estratificación de riesgo del síndrome coronario agudo mediante CT-proET-1 en combinación con NTproBNP | |
| ES2652027T3 (es) | Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II | |
| Cheng et al. | N-terminal pro-brain natriuretic peptide and cardiac troponin I for the prognostic utility in elderly patients with severe sepsis or septic shock in intensive care unit: A retrospective study | |
| Cataliotti et al. | Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling | |
| ES2430218T3 (es) | Diagnóstico y estratificación de riesgo mediante NT-proET-1 | |
| Vargas et al. | Copeptin for the early rule-out of non-ST-elevation myocardial infarction | |
| Montoro-García et al. | Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy | |
| WO2006087373A1 (en) | Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions | |
| US20110111526A1 (en) | Pro-endothelin-1 for the prediction of impaired peak oxygen consumption | |
| US20200116708A1 (en) | Fatty acid binding protein 3 for the assessment of atrial fibrillation (af) | |
| Maurellet et al. | B-type natriuretic peptide in the management of heart failure | |
| JP5715641B2 (ja) | 急性胸痛を伴い、心筋梗塞を伴わない患者において、心虚血を診断およびモニターするための方法 | |
| Omland et al. | Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation. | |
| KR20210044257A (ko) | 심방 세동의 평가에서의 순환 bmp10 (골형성 단백질 10) | |
| WO2011054829A1 (en) | NT-pro ANP AND SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS | |
| EP2737320B1 (en) | MID-REGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE (MR-proANP) FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION WITH AN ONSET OF LESS THAN 48 HOURS AGO | |
| Nageh et al. | Interpretation of plasma brain natriuretic peptide concentrations may require adjustment for patient's age | |
| Montagnana et al. | Evaluation of cardiac involvement following major orthopedic surgery | |
| Bai et al. | Serum N‐terminal‐pro‐Brain Natriuretic Peptide Level and Its Clinical Implications in Patients with Atrial Fibrillation | |
| Pincott et al. | New biomarkers in heart failure | |
| Kaulgud et al. | Novel biomarkers for risk stratification of acute coronary syndromes | |
| Dutta et al. | Prognostic Value of NT-proBNP in Predicting Adverse In-hospital Outcomes among Patients of STEMI getting Thrombolytic therapy without Clinical Manifestation of Heart Failure | |
| Yan et al. | Revolutionizing cardiovascular care: the role of natriuretic peptides and neprilysin inhibition | |
| Ciurzyński et al. | Advanced systemic sclerosis complicated by pulmonary hypertension and complete atrioventricular block: a case report. | |
| Storrow | Advances in the diagnosis of CHF: new markers |